Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo

Conclusions: Our study demonstrated the therapeutic potential of hEND-CD3/BiTE and provided a novel approach to clinical cancer treatment.

Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Liping Zhong, Wei Shi, Lu Gan, Xiuli Liu, Yu Huo, Pan Wu, Zhikun Zhang, Tao Wu, Hongmei Peng, Yong Huang, Yongxiang Zhao, Yulin Yuan, Zhiming Deng, Hongliang Tang Tags: Research Paper Source Type: research